The preclinical toxicology of salmeterol hydroxynaphthoate

Human and Experimental Toxicology

Volumn 29, Issue 5, 2010, Pages 393-407

  Owen, K ^a   Beck, S L ^a   Damment, S J P ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Shire Pharmaceuticals   (United Kingdom)

Author keywords

Beta2 agonist; Carcinogenicity; Dog; Genotoxicity; Reproduction; Rodent; Salmeterol hydroxynaphthoate; Toxicity

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; SALMETEROL XINAFOATE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CHEMISTRY; CARCINOGENICITY; CLEFT PALATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; EXPERIMENTAL DOG; EYELID DISEASE; FEMALE; FETOTOXICITY; GENETIC TOXICOLOGY; GENOTOXICITY; HEMATOLOGIC DISEASE; LARYNX; LEIOMYOMA; MALE; MOUSE; MUSCLE HYPERTROPHY; MUSCLE TUMOR; NONHUMAN; ORGANOGENESIS; OVARY CYST; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; REPRODUCTIVE TOXICITY; RESPIRATORY SYSTEM; SKELETON MALFORMATION; TACHYCARDIA; TOXICITY TESTING;

ADMINISTRATION, ORAL; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANIMALS; ANIMALS, INBRED STRAINS; CARCINOGENS; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; HYPERTROPHY; INHALATION EXPOSURE; LARYNX; MALE; MICE; MUSCLE, SKELETAL; MUTAGENS; RABBITS; RATS; REPRODUCTION; RESPIRATORY SYSTEM; TACHYCARDIA; TOXICITY TESTS;

ANIMALIA; CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS; RATTUS; RODENTIA;

EID: 77951181525     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327110363335     Document Type: Article

References (71)

1. Rabe KF State of the art in β2-agonist therapy: a safety review of long acting agents. Int J Clin Pract 2003 ; 57: 689-697.
2. Masoli M., et al. The global burden of asthma: executive summary of the Global Initiative for Asthma (GINA). Dissemination Committee Report. Allergy 2004 ; 59: 469-478.
3. Chung KF Role of inflammation in the hypereactivity of the airways in asthma. Thorax 1986 ; 41: 657-662.
4. Rabe KF, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD Executive Summary. Am J Resp Crit Care Med 2007 ; 176: 532-555.
5. Lotvall J. Pharmacological similarities and differences between beta2-agonists. Resp Med 2001 ; 95 (Suppl B). S7 - S11.
6. Man WDC, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004 ; 59: 471-476.
7. Martinez FD Safety of long-acting β-agonists - an urgent need to clear the air. New Engl J Med 2005 ; 353: 2637-2639.
8. Nelson HS, et al. The Salmeterol Multicenter Asthma Research Trial (SMART): a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006 ; 129: 15-26.
9. Matera MG, Cazzola M. Ultra-long-acting β2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs 2007 ; 67: 503-515.
10. Global strategy for asthma management and prevention, Global Initiative for Asthma (GINA), updated 2009. http://www.ginasthma.org ; accessed 31st jan 2010.
11. van der Woude HJ, Aalbers R. Long acting beta2-agonists. Comparative pharmacology and clinical outcomes. Am J Resp Med 2002 ; 2: 55-74.
12. Brogden RN, Faulds D. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991 ; 42: 895-912.
13. Johnson M. Salmeterol: a novel drug for the treatment of asthma. Agents Actions 1991 ; 34: 79-95.
14. Newman SP, et al. Deposition of pressurised aerosols in the human respiratory tract. Thorax 1981 ; 36: 52-55.
15. Peto R., Pike MC, Day NE, et al. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Supplement 2, Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal, Lyon, 1980, IARC Press, pp. 311-426.
16. Lewis DJ Factors affecting the distribution of tobacco smoke-induced lesions in the rodent larynx. Toxicol Lett 1981 ; 9: 189-194.
17. Gopinath C., Prentice DE, Lewis DJ Atlas of experimental toxicological pathology. Norwell, MA: MTP Press, 1987, p. 22-29.
18. Cder, Foradil Aerolizer (Formoterol). NDA 20-831. FDA Freedom of Information Office. http://www.fda.gov/cder/approval/index.htm (approval date, 16 February 2001; posted 15 May 2001). Pharmacol Rev, 2001.
19. Howarth PH, George CF Adverse effects of bronchodilator drugs. Adv Drug React Acute Poisoning Rev 1983 ; 2: 25-49.
20. Hall JA, Petch MC, Brown MJ Intracororonary injections of salbumtamol demonstrate the presence of functional β2-adrenoceptors in the heart. Circ Res 1989 ; 65: 546-553.
21. Scarpace PJ, Abrass IB Desensitisation of adenylate cyclase and down regulation of beta adrenergic receptors after in vivo administration of beta agonist. J Pharmacol Exp Ther 1982 ; 223: 327-331.
22. Pittman RN, Reynolds EE, Molinoff PB Relationship between intrinsic activities of agonists in normal and desensitised tissue and agonist-induced loss of beta-adrenergic receptors. J Pharmacol Exp Ther 1984 ; 230: 614-618.
23. Maconochie JG, et al. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol? Br J Clin Pharmacol 1994 ; 37: 199-204.
24. Balazs T., et al. The cardiotoxic effects of pressurized aerosol isoproterenol in the dog. Toxicol Appl Pharmacol 1973 ; 26: 407-417.
25. Pagano VT, Inchisoa MA Cardiomegaly produced by chronic beta-adrenergic stimulation in the rat: Comparison with alpha-adrenergic effects. Life Sci 1977 ; 21: 619-624.
26. Jeppsson AB, Waldeck B., Widmark E. Further studies on the cardiomegaly induced by beta-adrenergic agonists. Acta Pharmacologica et Toxicologica 1986 ; 58: 121-125.
27. Maconochie JG, Foster JK Dose-response study with high-dose inhaled salmterol in healthy subjects. Br J Clin Pharmacol 1992 ; 33: 342-345.
28. Bennett JA, Tattersfield AE Time course and relative dose potency of systemic effects from salbumatol and salmeterol in healthy subjects. Thorax 1997 ; 52: 458-464.
29. Poynter D., Spurting NW Some cardiac effects of beta-adrenergic stimulants in animals. Postgrad Med J 1971 ; 47 (Suppl): 21-24.
30. Reeds PJ, et al. Stimulation of muscle growth by clenbuterol: Lack of effect on muscle protein biosynthesis. Br J Nutr 1986 ; 56: 249-258.
31. Emery PW, et al. Chronic effects of beta-adrenergic agonists on body composition and protein synthesis in the rat. Biosci Rep 1984 ; 4: 83-91.
32. Maltin CA, Deldray MI, Reeds PJ The effect of a growth promoting drug, clenbuterol, on fibre frequency and area in hind limb muscles from young male rats. Biosci Rep 1986 ; 6: 239-299.
33. Waterfield CJ, et al. The biochemical effects of clenbuterol: With particular reference to taurine and muscle damage. Eur J Pharmacol 1995 ; 293: 141-149.
34. Lightfoot RM The musculoskeletal system. In: Turton J, Hooson J (eds). Target organ pathology, a basic text. London: Taylor and Francis, 1998, p. 239.
35. Shrewsbury S., Hallett C. Salmeterol 100 1/4g: an analysis of its tolerability in single and chronic dose studies. Ann Allergy Asthma Immunol 2001 ; 87: 465-473.
36. Goldberg R., et al. Metabolic responses to selective Beta-adrenergic stimulation in man. Postgrad Med J 1975 ; 51: 53-58.
37. Phillips PJ, et al. Metabolic and cardiovascular side effects of beta-adrenoceptor agonists, salbutamol and rimiterol. Br J Clin Pharmacol 1980 ; 9: 483-491.
38. Kutti J., et al. Effects of beta-receptor stimulation on the platelet count. Br Med J 1973 ; 4: 612.
39. Ingram GIC, et al. Factor VIII activity and antigen, platelet count and biochemical changes after adrenoceptor stimulation. Br J Haematol 1977 ; 35: 81-100.
40. Emstrom U., Sandberg G. Effects of adrenergic alpha-and beta-receptor stimulation on the release of lymphocytes and granulocytes from the spleen. Scand J Haematol 1973 ; 11: 275-286.
41. Gader AMA. The effects of β-adrenergic blockade on the responses of leucocyte counts to intravenous epinephrine in man. Scand J Haematol 1974 ; 13: 11-16.
42. Athens JW, et al. Leukokinetic studies IV: the total blood circulating and marginal granulocyte pools and granulocyte turnover rate in normal subjects. J Clin Investig 1961 ; 40: 989-995.
43. Jedrzejczak WW, Sulek K., Siekierzynski M. Mobilization of the marginal pool of neutrophils with epinephrine. Results in healthy persons, patients with neutropenias, patients with neutrophilias, and patients with changes in neutrophil count induced by cancer chemotherapy. Haematologica 1979 ; 64: 586-596.
44. Whitehurst VB, et al. Enhancement of acute myocardial lesions by asthma drugs in rats. Toxicol Pathol 1994 ; 22: 72-76.
45. Hoftbrand AV Iron. In: AV Hoftbrand and SM Lewis (eds.) Postgraduate haematology, 2 nd edn. London: William Heinemann Medical Books Ltd, 1981, p. 35-71.
46. Amemiya K., et al. Toxicology of matbuterol. Arzneimittelforsch 1984 ; 34: 1680-1684.
47. Dudley RE, et al. One-month toxicity study of tolbuterol hydrochloride in rats and dogs. Fund Appl Toxicol 1989 ; 13: 694-701.
48. Andersson K-E., Ingermasson I., Persson CGA. Relaxing effects of β-receptor stimulators in isolated, gravid human myometrium. Life Sci 1973 ; 13: 335-344.
49. Nishimura M., Iizuka M., Kast A. Repairability of wavy ribs in rat offspring. Arzneimittelforsch 1982 ; 32: 1518-1522.
50. Sterz H., et al. A postulated mechanism of beta sympathomimetic induction of rib and limb anomalies in rat fetuses. Teratology 1985 ; 31: 401-412.
51. Palmer AY Spontaneous malformations of the New Zealand White Rabbit: the background to safety evaluation tests. Lab Animals 1968 ; 2: 195-206.
52. Hirsch KS, Fritz HI Teratogenic effects of mescaline, epinephrine and norepinephrine in the hamster. Teratology 1981 ; 23: 287-291.
53. Lovatt-Evans C. Principles of human physiology. London: Churchill Press, 1945.
54. Berkenbosch F., et al. Beta adrenergic stimulation induces an increase of the plasma levels of immuno reactive alpha-MSH, beta-endorphin, ACTH and corticosterone. Life Sci 1981 ; 29: 2249-2256.
55. Fraser FC, Fainstat TD Production of congenital defects in the offspring of pregnant mice treated with cortisone. Pediatrics 1951 ; 8: 527-533.
56. Freysz H., et al. A long-term evaluation of infants who received a betamimetic drug while in utero. Journal of Perinatal Med 1977 ; 5: 94.
57. Svenningsen NW, Holmquist P., Ingermarsson I. Antenatal management of terbutaline: effects on infants born preterm. J Singapore Pediatr Soc 1985 ; 27: 208-214.
58. Schatz M., et al. The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol 1997 ; 100: 301-306.
59. Jones KL, et al. Salmeterol use and pregnancy outcomes: A prospective multicenter study. J Allergy Clin Immunol 2002 ; 109: S156.
60. Jack D., Poynter D., Spurling NW Beta-adrenoceptor stimulants and mesovarium leiomyomas in the rat. Toxicology 1983 ; 27: 315-320.
61. Nelson LW, Kelly WA Mesovarian leiomyomas in rats in a chronic toxicity study of soterenol hydrochloride. Vet Pathol 1971 ; 8: 452-457.
62. Sells DM, Gibson JP Carcinogenicity studies with medroxalol hydrochloride in rats and mice. Toxicol Pathol 1987 ; 15: 457-467.
63. Gibson JP, et al. Induction of uterine leiomyomas in mice by medroxalol and prevention by propanolol. Toxicol Pathol 1987 ; 15: 468-473.
64. Libretto SE A review of the toxicology of salbutamol (albuterol). Arch Toxicol 1994 ; 68: 213-216.
65. Chung HC, Woodward JK Mouse ueterine muscle as a model for studying β2-adrenoceptor mediated relaxation. J Autonomic Pharmacol 1984 ; 4: 17-25.
66. Apperley GH, et al. Characterisation of the beta adrenoceptors in the mesovarium of the rat. Br J Pharmacol 1978 ; 63: 345.
67. Fallahzadeh H., Dockerty M., Lee R. Leiomyoma of the ovary. Report of five cases and review of the literature. Am J Obstet Gynecol 1972 ; 113: 394-398.
68. Ross MH, Lustbader ED, Bras G. Contribution of body weight and growth to risk of anterior pituitary gland tumours in the rat. J Nat Cancer Inst 1983 ; 70: 1119-1125.
69. Roe FJC, et al. Risks of premature death and cancer predicted by body weight in early life. Hum Exp Toxicol 1991 ; 10: 285-288.
70. Tucker MJ The effect of long-term food restriction on tumours in rodents. Int J Cancer 1979 ; 23: 803-807.
71. Aguado LI, Petrovic SL, Ojeda SR Ovarian β-adrenergic receptors during the onset of puberty: characterisation, distribution and coupling to steroidogenic responses. Endocrinology 1982 ; 110: 1124-1132.